Neogenomics, Inc.
NEO
$7.88
-$0.10-1.25%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 35.52% | -53.28% | -141.88% | 4.21% | -6.97% |
| Total Depreciation and Amortization | -9.86% | -8.61% | -4.66% | -2.95% | -0.94% |
| Total Amortization of Deferred Charges | -47.68% | -47.81% | -31.50% | 1.38% | 1.39% |
| Total Other Non-Cash Items | -1.83% | 80.76% | 189.14% | 20.58% | 9.45% |
| Change in Net Operating Assets | -284.28% | 91.01% | 579.25% | -7.59% | -211.81% |
| Cash from Operations | -86.30% | -3.92% | 46.34% | 2.27% | -44.89% |
| Capital Expenditure | 32.14% | 23.01% | 51.65% | 19.43% | -64.36% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -108.15% | 16.71% | -85.29% | -59.92% | -74.72% |
| Cash from Investing | -15.33% | 92.12% | -227.36% | -75.49% | -131.79% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -87.83% | -54.89% | -- | 16.30% | 6.65% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -39.47% |
| Cash from Financing | -37.26% | -35.00% | -10,396.69% | 16.30% | -45.91% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -189.62% | 36.01% | -926.34% | -96.88% | -86.15% |